Biotech · Private company · Mountain View, CA, US

IGM Biosciences, Inc.

SEC CIK 0001496323

Track this companyFree. Adds IGM Biosciences, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials80 recruiting or active

Pipeline programs13From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline13

A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory MyopathiesPHASE1 · TERMINATED · started May 29, 2024ClinicalTrials.gov NCT06524687 · fetched Nov 12, 2026
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple MyelomaPHASE1 · TERMINATED · started Aug 29, 2023ClinicalTrials.gov NCT05908396 · fetched Nov 12, 2026
A Study of Imvotamab in Severe Systemic Lupus ErythematosusPHASE1 · TERMINATED · started Aug 15, 2023ClinicalTrials.gov NCT06041568 · fetched Nov 12, 2026
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid ArthritisPHASE1 · TERMINATED · started Mar 15, 2023ClinicalTrials.gov NCT06087406 · fetched Nov 12, 2026
Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory CancerPHASE1 · COMPLETED · started Jan 10, 2023ClinicalTrials.gov NCT05702424 · fetched Nov 12, 2026
Evaluation of IGM-6268 in Healthy VolunteersPHASE1 · TERMINATED · started Dec 7, 2021ClinicalTrials.gov NCT05160402 · fetched Nov 12, 2026
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed CancersPHASE1 · TERMINATED · started Sep 23, 2020ClinicalTrials.gov NCT04553692 · fetched Nov 12, 2026
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin LymphomaPHASE1_PHASE2 · TERMINATED · started Sep 30, 2019ClinicalTrials.gov NCT04082936 · fetched Nov 12, 2026